Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GoodRx vs Ro

By GLP-1 ScorecardUpdated

GoodRx
Site position #132

Lower grade

Ro
Site position #38

Higher grade

Score comparison

Ro has the higher recorded score — 80.2/100 to 69.6/100.

Ro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ro is worth comparing for branded access and insurance help, but the membership price is only one part of the bill.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueGoodRx +12
80
68
Dose & formulationRo +16
70
86
Clinical oversightRo +17
69
86
Labs & monitoringRo +31
51
82
FulfillmentRo +3
81
84
Contract termsRo +25
55
80
GoodRx · top barRo · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricGoodRxRo
WeighScore69.6/10080.2/100
GradeCB−
Site position#132#38
SemaglutideWegovy pill from $149 at 1.5 mg; injection $199 for two qualifying fills then $349. Separate $39/mo care fee if subscribed; dose/offer conditions apply.Varies (branded medication plus separate membership)
TirzepatideZepbound KwikPen advertised from $299; dose-specific and 28-day supply/refill conditions apply. Separate $39/mo care fee if subscribed; confirm pharmacy quote.Varies (branded medication plus separate membership)
CoveragePrescription savings at participating U.S. pharmacies; Care Direct weight-loss prescribing excludes Alabama and Louisiana. Confirm the specific treatment and pharmacy.Multi-state
Brand-name accessYesYes
Oral / sublingualYesYes
GoodRx

Site position #132 · C

Strengths

  • Free prescription discounts can be used without purchasing the weight-loss care subscription
  • Current Care Direct menu names oral Wegovy, injectable Wegovy/HD, Foundayo tablets and Zepbound KwikPen
  • Publishes a separate $39 monthly care fee rather than presenting it as the medication price
  • Official terms name possible medical groups and dispensing pharmacies; the guide explains pharmacy selection

What to consider

  • Medication is extra; dose offers do not establish continuing cost. Foundayo and Zepbound self-pay card savings end December 31, 2026
  • The Zepbound page has an inconsistent 10 mg lowest-dose label; confirm device, strength and selected quote
  • Support and terms differ on the initial care-charge trigger; renewals are automatic and cancellation requires at least one day’s notice
  • Care Direct weight-loss treatment excludes Alabama and Louisiana, and the guide says no insurance prior-authorization submissions
  • Actual dispensing branch, lab costs and refill timing still require confirmation; canceling does not guarantee a refund
Ro

Site position #38 · B−

Strengths

  • Brand-name access + insurance support
  • Oral options
  • Current pricing separates membership from medication charges

What to consider

  • Membership starts at $39 for the first month, then $74–149 per month depending on term; the $74 rate requires annual prepayment
  • Medication is extra; the total depends on the selected drug and payment arrangement
  • Membership cancellation requires at least 48 hours before renewal; paid membership fees are described as nonrefundable

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard